Onset of efficacy of montelukast in seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 26, Issue 1, 2005, Pages 41-46

  Weinstein, Steven F ^a,d   Philip, George ^b   Hampel Jr , Frank C ^c   Malice, Marie Pierre ^b   Swern, Arlene S ^b   Dass, Balachandra ^b   Reiss, Theodore F ^b  

^a Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Central Texas Health Research   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONTELUKAST; PLACEBO;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIODICITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCORING SYSTEM; SPRING; STATISTICAL SIGNIFICANCE;

ACETATES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 17144430933     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 28(suppl)2:3-10, 1998.
2. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl 5): S147-S334, 2001.
3. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 161:S133-S136, 2000.
4. Sander C, and Rajakulasingam K. Leukotriene receptor antagonists for the treatment of allergic rhinitis. Clin Exp Allergy 32:4-7, 2002.
5. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med 158:1213-1220, 1998.
6. Reiss TF, Knorr B, Malmstrom K, et al. Clinical efficacy of montelukast in adults and children. Clin Exp Allergy Rev 1:264-273, 2001.
7. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000.
8. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88:592-600, 2002.
9. Philip G, Malmstrom K, Hampel FC Jr, et al. Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 32:1020-1028, 2002.
10. van Adelsberg J, LaForce CF, Weinstein SF, et al. Randomized controlled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 90:214-222, 2003.
11. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 58:1268-1276, 2003.
12. Center for Drug Evaluation and Research. Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Rockville, MD: Center for Drug Evaluation and Research, United States Department of Health and Human Services, April 2000.
13. Berkowitz RB, Roberson S, Zora J, Capano D, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20:167-172, 1999.
14. Georgitis JW, Meltzer EO, Kaliner M, et al. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma Immunol 84:451-459, 2000.
15. Day JH, Briscoe MP, Rafeiro E, et al. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 105:489-494, 2000.
16. Berkowitz RB, Woodworth GG, Lutz C, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol 89:38-45, 2002.
17. Malice M P, Philip G, van Adelsberg J, et al. Montelukast for treating seasonal allergic rhinitis: Effect of pollen counts in 3 fall studies. J Allergy Clin Immunol 111(suppl 2):S144, 2003.
18. Chervinsky P, Philip G, Malice M-P, et al. Montelukast for treating fall allergic rhinitis: Effect of pollen exposure in three studies. Ann Allergy Asthma Immunol 92:367-373, 2004.
19. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 54:64-69, 1999.
20. Day JH, Briscoe MP, Rafeiro E, and Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 58:109-118, 2004.